Clinical Study Synopsis
|
|
- Cameron Stephens
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayer.com apply to the contents of this file.
2 Study no Page: 1 of 8 Date of study report: 30 Apr 2018 Study title: Sponsor s study number: NCT number: EudraCT number: Sponsor: Clinical phase: Study objectives: REGO-ACT, Assessment of physical activity during therapy with regorafenib for metastatic colorectal cancer NCT Not Applicable Bayer Non-interventional Primary Objective: To assess the average amount of physical activity of patients with mcrc during regorafenib treatment as measured using pedometer data and International Physical Activity Questionnaire (IPAQ) results. The primary endpoints were the amount of physical activity during regorafenib treatment based on: Median number of steps/day measured on a 1-week basis (i.e., from Days 1 7) as well as for additional 1-week intervals through the end of the study using a pedometer Median number of steps/day measured on a 4-week basis (i.e., from on Days 1 28) as well as for additional 4-week intervals through the end of the study using a pedometer International Physical Activity Questionnaire (IPAQ) score on Days 28, 56, and 84 in metabolic equivalents of a task (MET) minutes/week Delta IPAQ between Days 1 and 28, Days 1 and 56, and Days 1 and 84 in MET minutes/week Secondary Objectives: Potential secondary objectives of this study were to assess the relation between the level of physical activity on the one hand and quality of life (QoL, as assessed using the EQ-5D-3L questionnaire), the frequency of the adverse event (AE) fatigue, disease control rate (DCR), progressionfree survival (PFS), and overall survival (OS) on the other. The secondary endpoints were the relation between physical activity (in terms of both the median number of steps/day and MET minutes/week) and
3 Study no Page: 2 of 8 QoL of life as measured by the EQ-5D-3L in CORRELATE (NCT , Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings ) Incidence of the AE fatigue as reported in CORRELATE DCR, defined as the percentage of patients whose best response was a complete response (CR), partial response (PR), or stable disease (SD); stable disease must have been at least 6 weeks in duration as assessed in CORRELATE. PFS, defined as the time from the date of the first regorafenib dose to the date of progressive disease (PD) or death as estimated by the Kaplan-Meier method observed in CORRELATE OS, defined as the time from the start of regorafenib therapy to the date of death in CORRELATE. Patients who had not died by the analysis cut-off date were censored at their last contact date (Kaplan-Meier method) in CORRELATE. Test drug: Name of active ingredient(s): Dose: Route of administration: Duration of treatment: Reference drug: Indication: Diagnosis and main criteria for inclusion: Regorafenib (Stivarga, BAY ) Regorafenib Treatment was done according to the label approved by EMA. The recommended dose of regorafenib is 160 mg taken once daily for 3 weeks, followed by 1 week off therapy. In this study, dosing decisions were at the discretion of the treating physicians. Oral The planned observation period for each patient enrolled into the study was 3 months (84 days) from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first. Not Applicable Metastatic Colorectal cancer Only patients included into CORRELATE in Austria may participate in this local study. Inclusion criteria of OS CORRELATE: Patients had been diagnosed with mcrc who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom a treatment
4 Study no Page: 3 of 8 Study design: Methodology: Study center(s): Publication(s) based on the study (references): decision in favor of regorafenib had been made per investigator s routine treatment practice. had given signed informed consent for enrolment into CORRELATE. Inclusion criteria of REGO-ACT: Patients enrolled in CORRELATE in Austria Signed patient informed consent for enrolment into REGO-ACT This is a local, prospective, non-interventional, multi-center, single arm pilot study All study sites participating in and enrolling patients into the international non-interventional CORRELATE study were offered participation in REGO-ACT. The purpose of the CORRELATE study was to investigate the safety and effectiveness of regorafenib in routine clinical practice. Overall, 5 Austrian study sites participated in this study. All of the 25 patients enrolled into this study had initially been enrolled into CORRELATE. Subjects filled in the International physical activity questionnaire at baseline, and then at each visit according to physician s discretion (following time schedule is recommended: every 28 days up to 84 days from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first). Additionally, for objective measurement of physical activity all patients received a CE-certified pedometer at baseline. The pedometer should be worn for 84 days from enrolment into REGO-ACT to the end of REGO-ACT, regorafenib treatment, withdrawal of consent, or death, whichever occurred first. Data capture of the pedometer will be performed at each visit. The aim is to quantitatively evaluate the amount of physical activity in this patient population. 5 study sites in Austria None at the time of report creation Study period: Study Start Date: 20-Jan-2015 Study Completion Date: 08-Sep-2016 Early termination: No
5 Study no Page: 4 of 8 Number of subjects: Planned: 25 Criteria of evaluation: Efficacy: Safety: Statistical methods: Substantial protocol changes: Analyzed: 25 Primary: The number of steps/day as measured using a pedometer The self-administered International Physical Activity Questionnaire (IPAQ) MET minutes/week as recorded in the REGO-ACT study. Secondary: the relation between physical activity (in terms of both the median number of steps/day and MET minutes/week) and QoL of life as measured by the EQ-5D-3L in CORRELATE Incidence of the AE fatigue as reported in CORRELATE DCR, defined as the percentage of patients whose best response was a complete response (CR), partial response (PR), or stable disease (SD); stable disease must have been at least 6 weeks in duration as assessed in CORRELATE. PFS, defined as the time from the date of the first regorafenib dose to the date of progressive disease (PD) or death as estimated by the Kaplan- Meier method observed in CORRELATE OS, defined as the time from the start of regorafenib therapy to the date of death in CORRELATE. Patients who had not died by the analysis cutoff date were censored at their last contact date (Kaplan-Meiermethod) in CORRELATE. Adverse events All data were analyzed using descriptive statistics. Study was conducted according to final study protocol dated 02 Jan 2015 and included no substantial amendments Subject disposition and baseline Of the 25 patients enrolled, 16 patients (64%) were male and 9 patients (36%) were female. The mean age was 62.4±10.9 years (range, years).
6 Study no Page: 5 of 8 Efficacy evaluation [Primary]: Median number of steps/day Pedometer data were available for 22 of the 25 enrolled patients. The number of days with available pedometer data varied widely among the 22 patients, ranging from 6 to 100. In individual patients, the number of days with pedometer data slightly exceeded the number of days of study participation, with some patients returning the pedometer after the official study end and still wearing the pedometer during this time. Of the 11 patients who participated in the study for the entire scheduled duration of 84 days, 3 patients had pedometer results for 82, 84, and 100 days, 13 patients had pedometer data for days, and 6 patients had pedometer data for 6 13 days. A total of 16 patients had pedometer data for at least 21 days. The median number of steps/day measured on a 1-week and 4-week basis remained relatively constant throughout the course of the study. However, wide variations between the minimum and maximum numbers of steps were seen (e.g., between 31 and 8131 steps/day on Days 1 7). From this analysis, it was unclear whether these were intra- or interindividual variations. Therefore, we also specifically looked at the step counts of each individual patient. When looking at patients individually, considerable variations were seen in the weekly and monthly median number of steps/day, particularly between patients. Interindividually, baseline median step counts/day on a 1-week basis ranged between 31 and When only patients with at least 3 weeks of available pedometer data were looked at (n=16), the baseline median number of steps/day on a 1- week basis ranged from 130 to 7239; 13 of these 16 patients had step counts above 1200, thus being well within the range reported for special populations in the literature. Intraindividually, median step counts on a 1-week basis varied over time in some patients, but remained relatively constant in others. To better understand the intra- and interindividual variations in the median number of steps/day seen at a 1-week basis, daily step counts per patient were also analyzed. Intraindividually, step counts/day in some patients varied by several thousands of steps/day, e.g., from 10 to 10,934 in one patient or from 2,093 to 14,931 in another patient). Interindividually, maximum step counts/day varied between 401 and 14,931. Although intraindividual step counts varied considerably on a day-to-day basis, the median number of steps/day analyzed on a 1-week basis appears to provide a good indication of a patient s general level of activity, with weekly step counts in the range of several thousands in some and several hundreds in other patients.
7 Study no Page: 6 of 8 IPAQ results Of the 25 patients, 21 patients completed the IPAQ questionnaire at least once. During data analysis, it was found that many completed questionnaires were not directly evaluable because of implausible or incomplete responses. As a result of these inconsistencies, only a minority of completed IPAQs were considered to have yielded reliable results. At the same time, visit intervals varied considerably between patients, and the number of patients with available IPAQ results dropped throughout the course of the study. The primary endpoints including IPAQ results were therefore considered to defy reliable statistical analysis. [Secondary]: The relation between physical activity and other variables was analyzed only on the basis of the median number of steps/day, but not on the basis of IPAQ results. Relation between the median number of steps/day and QoL as measured using the EQ-5D-3L in CORRELATE To determine the relation between the median number of steps/day and QoL as measured by the EQ- 5D-3L, only EQ-VAS values were used. At the beginning of the study, moderately strong correlations between EQVAS and the median number of steps/day on Days 1 7 and 8 14 were seen. Moderately strong correlations between EQ-VAS and the median number of steps/day on Days 8 14 and were also found at time point 3 of EQ-VAS assessment. Relation between step counts and the incidence of the AE fatigue as reported in CORRELATE Of the 25 enrolled patients, 14 patients (56%) reported fatigue in the course of the CORRELATE study. Of these 14 patients, 10 patients experienced fatigue during the course of the REGO-ACT study, and only 8 patients reported fatigue within their individual time periods of pedometer use. No significant correlations between the median number of steps/day and the presence of fatigue were found. Overall, however, patient numbers were too small and periods of observation too short to draw statistically reliable conclusions on the correlation between step counts and fatigue. Relation between the median number of steps/day and DCR, PFS, or OS as reported in CORRELATE Due to rapidly decreasing numbers of patients with pedometer data throughout the course of REGO- ACT, the high intra- and interindividual variations in step counts, and still incomplete CORRELATE response data at the end of the REGO-ACT study, correlations between the median number of steps/day and DCR, PFS, and OS could not reliably be determined. However, looking at patients individually, relations between step counts and DCR, PFS, or OS appear unlikely, with some patients displaying comparatively high levels of walking activity almost up to the time of their
8 Study no Page: 7 of 8 disease progression or death and other patients showing very low levels or short durations of walking activity despite comparatively high levels of QoL or longer survival. Safety evaluation To avoid duplicate reporting, safety reporting was performed as part of the CORRELATE study only. Overall conclusions The primary aim of this pilot study was to obtain data on the extent of physical activity of patients with mcrc during regorafenib therapy. The study showed that, despite the severity of their disease, patients generally displayed remarkable levels of walking activity, with baseline levels in most patients within the range for special populations reported in the literature. In view of the widely differing baseline levels of walking activity between patients, the aim of exercise programs for the special patient population included in this study should be to tailor interventions to the specific needs, physical capacity, and preferences of each individual patient rather than prescribing normative stepcount targets for the entire population. While the pedometer results of this study established a baseline step count for the majority of our patients, a number of factors most importantly technical issues related to step counting and the lack of patient supervision due to the non-interventional nature of this study limited the utility of the pedometer in measuring long-term physical activity levels in this study and should be addressed in future research. The key limitations of this pilot study were its small sample size and its non-interventional character, which resulted in a relatively large proportion of missing data, widely varying visit intervals, implausible IPAQ entries, and ultimately only 3 patients with pedometer results spanning the entire 84-day observation period scheduled for the study. In view of these limitations, some of the predefined endpoints may have been too specific or complex and were ultimately not analyzable as originally planned. For example, completing the IPAQ, a tool also used in this study to estimate the patients level of physical activity, appeared to have been too demanding to complete for many patients, and future studies may benefit from simpler tools to document patient-reported levels of exercise. By contrast, the EQ-5D-3L questionnaire used in this study to measure the patients QoL is a concise and easyto-use tool, and its EQ-VAS component was the only variable in this study to show moderate correlations with the pedometer data obtained, and the relations between step counts and measures of subjective well-being therefore clearly warrant additional research. One focus of this study was on a common side effect of treatment with regorafenib, i.e., fatigue, which can markedly affect a patient s well-being and interfere with daily life. Available evidence suggests that physical exercise is beneficial for cancer patients and may mitigate cancer-related fatigue. Although this pilot study did not find a correlation between fatigue and walking activity, this may, at least in part, have been due the methodological aspect of fatigue having been reported as an AE during follow-up visits rather than being more closely and consistently monitored throughout the study, preferably on a daily basis. Therefore, future research may benefit from the use of tools
9 Study no Page: 8 of 8 specifically developed to closely monitor fatigue. In addition, other AEs, such as pain, diarrhea, vertigo, dyspnea, or palmar-plantar erythrodysesthesia, may also have an effect on a patient s ability or willingness to exercise and merit inclusion in future studies. Overall, the preliminary data on the individual levels of walking activity of mcrc patients and the methodologically insights from this pilot study can serve as a starting point for the development of tailored exercise prescription programs designed to alleviate cancer-related side effects and improve patient well-being and quality of life.
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEMERGENCY USE 03/02/2016
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program EMERGENCY USE 03/02/2016 Emergency Exemption for an Investigational Drug or Biologic or Unapproved Device Emergency use of an investigational
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human, Recombinant) Reference Number: CP.CPA.76 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationSOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS
University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationIRB Training October 22, 2015
Humanitarian Use Devices & Humanitarian Device Exemptions IRB Training October 22, 2015 What is a Humanitarian Use Device (HUD)? Intended to benefit patients in the treatment or diagnosis of diseases or
More informationHuman Research Protection Program Policy
Page 1 of 6 POLICY CONTINUING REVIEW BY THE IRB The University of Cincinnati Institutional Review Board (IRB) shall conduct continuing review of human participant research at intervals appropriate to the
More informationUNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH I. PURPOSE This document outlines the University of Tennessee Health Science Center Institutional
More informationAMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016 The Duke University Health System Institutional Review Board (DUHS IRB) requires that
More informationDate Effective 4/21/2008 Identification
OHSU Research Integrity Office Human Research Protection Program Policies & Procedures Title: Research with Medical Devices Date Effective 4/21/2008 Identification Supersedes P&P dated: Page 1 of BACKGROUND
More informationSecond Quarter 2018 Results Call Corporate Update & Financial Results. August 7, 2018
Second Quarter 2018 Results Call Corporate Update & Financial Results August 7, 2018 Forward-Looking Statements BioCryst s presentation may contain forward-looking statements, including statements regarding
More informationTHERAPEUTIC USE EXEMPTION POLICY U.S. ANTI-DOPING AGENCY. Effective JANUARY 1, (Revised June 21, 2018)
THERAPEUTIC USE EXEMPTION POLICY U.S. ANTI-DOPING AGENCY Effective JANUARY 1, 2018 (Revised June 21, 2018) 1. GENERAL PRINCIPLES The United States Anti-Doping Agency ( USADA ) Policy for Therapeutic Use
More informationSFHCHS78 Administer oxygen safely and effectively
Overview This standard is about the safe and effective administration of oxygen in all healthcare settings, at home and in any environment where an individual requires oxygen therapy. Users of this standard
More informationSOP Title Review of Research: Devices for Humanitarian Uses
SOP Title Review of Research: Devices for Humanitarian Uses Purpose This document describes the National Jewish Health IRB review of Humanitarian Use Devices and Humanitarian Device Exemptions. Scope Humanitarian
More informationPolicy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013; 05/01/2016; 10/16/2018
University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 42 Title: Investigational Devices Date of Last Revision: 06/12/2008; 07/22/2010; 05/29/2013;
More information7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL
7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL 7.1 OBJECTIVE To describe the policies and procedures for reviewing a modification or a deviation/exception to a previously approved protocol.
More information2019 Canada Winter Games Synchronized Swimming Technical Package
2019 Canada Winter Games Synchronized Swimming Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility
More informationThe Effect of a Seven Week Exercise Program on Golf Swing Performance and Musculoskeletal Screening Scores
The Effect of a Seven Week Exercise Program on Golf Swing Performance and Musculoskeletal Screening Scores 2017 Mico Hannes Olivier Bachelor of Sport Science Faculty of Health Sciences and Medicine Bond
More informationIndependent Ethics Committees
GCP Independent Ethics Committees 1 GCP What is an Ethics Committee? An ethics committee is a committee formally designated to review and approve the initiation of a clinical research study involving human
More informationEustachian Tube Dysfunction Patient Questionnaire (ETDQ-7) Collection, Training and Utility
Eustachian Tube Dysfunction Patient Questionnaire (ETDQ-7) Collection, Training and Utility 2017 Acclarent, Inc. All rights reserved. 070561-170405 1 ETDQ-7: What is it? The ETDQ-7 is a disease-specific
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)
Study Management SM 302.00 STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval:
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH I. PURPOSE This document outlines the required elements of University of Tennessee
More informationYale University Human Research Protection Program
Yale University Human Research Protection Program HRPP Policy 700 Noncompliance, Suspension and Termination Responsible Office Office of Research Administration Effective Date: February 10, 2009 Responsible
More informationFlip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial
Flip-flop footwear with a moulded foot-bed for the treatment of foot pain: a randomised controlled trial Dr. Martin Spink, Ms. Angela Searle and Dr. Vivienne Chuter Podiatry department Faculty of Health
More informationCONTINUING REVIEW 3/7/2016
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program Introduction CONTINUING REVIEW 3/7/2016 Federal regulations require that DUHS has written procedures which the IRB will follow for (a) conducting
More informationSupplementary Online Content
Supplementary Online Content McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: a Randomized Clinical Trial.
More informationCurrent Status: Active PolicyStat ID: Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021
Current Status: Active PolicyStat ID: 4870880 Origination: 04/2018 Effective: 04/2018 Approved: 04/2018 Last Revised: 04/2018 Expiration: 04/2021 Owner: Policy Area: References: Suzanne Sharland-Hemmila:
More information2010 TRAVEL TIME REPORT
CASUALTY ACTUARIAL SOCIETY EDUCATION POLICY COMMITTEE 2010 TRAVEL TIME REPORT BIENNIAL REPORT TO THE BOARD OF DIRECTORS ON TRAVEL TIME STATISTICS FOR CANDIDATES OF THE CASUALTY ACTUARIAL SOCIETY June 2011
More informationOHRP Guidance on Written IRB Procedures
Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional
More information2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE
2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationJEPonline Journal of Exercise Physiologyonline
Walking Technique and Estimated VO 2 max Values 21 JEPonline Journal of Exercise Physiologyonline Official Journal of The American Society of Exercise Physiologists (ASEP) ISSN 1097-9751 An International
More information2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE
2015 CANADA WINTER GAMES CROSS COUNTRY SKIING & PARA-NORDIC TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and
More informationWayne State University Institutional Review Board
Wayne State University Institutional Review Board Subject Approvals, Serious & Continuing Non-Compliance and the Institutional Official s Responsibilities Administrative Approval: 07/2011; Office of the
More informationEffective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate
Policy Title: Initial Review of Human Subject Research Effective Date: January 16, 2012 Policy Number: Review Date: November 20, 2015 Section: Revised Date: November 2, 2015 Oversight Level: Corporate
More informationThe Impact of TennCare: A Survey of Recipients 2009
The Impact of TennCare: A Survey of Recipients 2009 Christopher Carty Research Associate, Center for Business and Economic Research William F. Fox Director, Center for Business and Economic Research and
More informationBaptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:
Baptist Health Institutional Review Board Study Closure Report (Expedited Review) (Please complete ALL sections of this form. Incomplete forms will be returned) Principal Investigator: E-mail: Phone #:
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationHumanitarian Use Devices Made Simple
May 25, 2017 Humanitarian Use Devices Made Simple Robert Romanchuk, BSHS, CIP, CCRC, CHRC, CCRCP IRB Vice Chairperson, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA
More informationSITE NAME: ISF DOCUMENT VERSION CHECKLIST Complete yes or no to confirm the presence or absence of each document specified.
1. TRIAL MANAGEMENT CTC Contact List 8 29/07/2016 Y N CTC Contact List (superseded) 7 29/09/2015 Y N CTC Contact List (superseded) 6 24/02/2015 Y N CTC Contact List (superseded) 5 03/09/2014 Y N CTC Contact
More information2017 Canada Summer Games Indoor Volleyball Technical Package
2017 Canada Summer Games Indoor Volleyball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,
More informationCONTINUING REVIEW CRITERIA FOR RENEWAL
1. POLICY Steering Committee approved / Effective Date: 9/2/19/19/11 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk,
More informationCambridge International Examinations Cambridge Ordinary Level
Cambridge International Examinations Cambridge Ordinary Level *9399919087* STATISTICS 4040/12 Paper 1 October/November 2015 Candidates answer on the Question Paper. Additional Materials: Pair of compasses
More informationAssessment of Guide Reporting & Preliminary Results of Lion Monitoring
Assessment of Guide Reporting & Preliminary Results of Lion Monitoring Mara Predator Project December 21 Sara Blackburn Laurence Frank maralions@gmail.com lgfrank@berkeley.edu SUMMARY The Mara Predator
More informationThe Onychomycosis Market (2018 Edition) September 2018
The Onychomycosis Market (2018 Edition) September 2018 The US Onychomycosis Market:Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis The US Market Analysis Competitive
More informationInstitutional Review Board - Restriction s Impo sed
('/(.s~ ll $L'P.VIC' s '0 ~t: 'o
More information2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package
2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility
More informationCSHCN Services Program Prior Authorization Request for Oxygen Therapy Form and Instructions
General Information CSHCN Services Program Prior Authorization Request for and Instructions Ensure the most recent version of the Prior Authorization Request for Oxygen Therapy form is submitted. The form
More informationIGEM/TD/2 Edition 2 with amendments July 2015 Communication 1779 Assessing the risks from high pressure Natural Gas pipelines
Communication 1779 Assessing the risks from high pressure Natural Gas pipelines Founded 1863 Royal Charter 1929 Patron: Her Majesty the Queen Communication 1779 Assessing the risks from high pressure Natural
More informationA review of 2015 fatal collision statistics as of 31 December 2015
A review of fatal collision statistics as of 31 December This report summarises the main trends in road fatalities that have emerged in. This has been prepared by the Road Safety Authority following analysis
More informationDeveloping very brief interventions (VBIs) to promote physical activity in primary care
Walk Walk Developing very brief interventions (VBIs) to promote physical activity in primary care Walk Walk Sally Pears BPS Division of Health Psychology Annual Conference, York 2014 Move Funder: NIHR
More informationRESEARCH PROTECTIONS OFFICE
Page 1 of 5 RESEARCH PROTECTIONS OFFICE Single IRB RPO Human Subjects Research Single IRB Single IRB Definitions Authorization Agreement/Reliance Agreement written agreement between two or more institutions
More informationNZQA unit standard version 1 Page 1 of 5. Demonstrate knowledge of hazardous substances relevant to Certified Handlers
Page 1 of 5 Title Demonstrate knowledge of hazardous substances relevant to Certified Handlers Level 5 Credits 6 Purpose This unit standard is for people preparing for, and intend to apply for, Certified
More informationIssue in IRB Approvals:
Issue in IRB Approvals: What are the obligations of investigators and the IRB in maintaining IRB approval? What are the consequences of a lapse in IRB approval? How does the IRB evaluate lapses in approval?
More informationHUMAN SUBJECTS INSTITUTIONAL REVIEW BOARD PROCEDURES
1 HUMAN SUBJECTS INSTITUTIONAL REVIEW BOARD PROCEDURES http://www.sjsu.edu/gradstudies/irb The Institutional Review Board (IRB) is a ten to fifteen member committee whose task is to review all research
More informationSalisbury District Hospital
The Effectiveness of Peroneal Nerve Functional Electrical STimulation (FES) for the Reduction of Bradykinesia in Parkinson s Disease: A Pragmatic Two Site Feasibility Study for a Single Blinded Randomised
More informationMinot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT
Minot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT Annual Updates, Revisions, or Project Completion/Termination Reports should by typed on no more than two
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationArkansas Tech University Institutional Review Board
Arkansas Tech University Institutional Review Board Presentation Agenda IRB 1001: The Basics Levels of IRB Review IRB Decisions The Process of Consent Open Discussion IRB 1001: The Basics Human Participant
More informationCoaching Applications The Effect of Intermittent Hypoxic Exposure plus Sea Level Swimming Training on Anaerobic Swimming Performance
J. Swimming Research, Vol. 19:2 (2012) Coaching Applications plus Sea Level Swimming Training on Anaerobic Swimming Performance Miller A.N. 1 and George K. 2 Department of Biomolecular and Sports Science,
More informationWaterford Soccer Club Travel Team Policies
Waterford Soccer Club Travel Team Policies Introduction The following document describes the policies which Waterford Soccer Club (WSC) uses to administer its Travel Soccer program. While the club by-laws
More informationThe IRB reviews and monitors human subjects research conducted by Columbia College Chicago faculty, staff, and students.
IRB FAQ s We hope that this FAQ will acquaint you with the basic policies and procedures of the IRB review and approval process. It is available to researchers from the Columbia College Chicago IRB. Although
More informationA. Evaluation of the written program
A. Evaluation of the written program Begin your audit with an evaluation of the written respiratory protection program. In addition to the operating procedures describing respirator selection and use in
More information2019 Canada Winter Games Wheelchair Basketball Technical Package
2019 Canada Winter Games Wheelchair Basketball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility
More informationUNIVERSITY OF GEORGIA Institutional Review Board
UNIVERSITY OF GEORGIA Institutional Review Board Continuing Review Number: Date: Author: Approved By: Page(s): UGAHRP-057-2 01/20/2017 HSO IRB Page 1 of 7 1. PURPOSE 1.1. The UGA IRB has developed this
More informationGuidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval
Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval Additional copies are available from: Office of Communication Division of Drug Information,
More information2017 Canada Summer Games Beach Volleyball Technical Package
2017 Canada Summer Games Beach Volleyball Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,
More informationAnnapolis Striders Winter Half Marathon Training Program TRAINING UPDATE 06
Annapolis Striders Winter Half Marathon Training Program TRAINING UPDATE 06 MICHAEL MYERS STRESSORS 02/10/2018 EIGHT-MILES TO JUMPERS AND BACK WITH A THINNER HERD TODAY S RUN On Saturday 10 February, 33
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More information2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package
2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility
More informationCONTINUING REVIEW CRITERIA FOR RENEWAL
1. POLICY Steering Committee approved / Effective Date: 9/2/15 The IRB conducts continuing review of research taking place within its jurisdiction at intervals appropriate to the degree of risk, but not
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute / IRB Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationRisk Factors Involved in Cheerleading Injuries
University of Arkansas, Fayetteville ScholarWorks@UARK Health, Human Performance and Recreation Undergraduate Honors Theses Health, Human Performance and Recreation 5-2016 Risk Factors Involved in Cheerleading
More information2017 Canada Summer Games Golf Technical Package
2017 Canada Summer Games Golf Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements, assist
More informationHUD and HDE Topics. Humanitarian Use Device and. Humanitarian Use Device. Humanitarian Device Exemption
Humanitarian Use Device Humanitarian Device Exemption Marian Serge, RN Division of Bioresearch Monitoring Center for Devices and Radiological Health Marian.Serge@fda.hhs.gov 1 HUD and HDE Topics Regulations//Guidance
More information2015 CANADA WINTER GAMES WHEELCHAIR BASKETBALL TECHNICAL PACKAGE
2015 CANADA WINTER GAMES WHEELCHAIR BASKETBALL TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility
More informationReduction of Speed Limit at Approaches to Railway Level Crossings in WA. Main Roads WA. Presenter - Brian Kidd
Australasian College of Road Safety Conference A Safe System: Making it Happen! Melbourne 1-2 September 2011 Reduction of Speed Limit at Approaches to Railway Level Crossings in WA Radalj T 1, Kidd B 1
More informationFigure 39. Yearly Trend in Death Rates for Drowning: NSW, Year
10.0 DROWNING 10.1 Deaths due to Drowning: The drowning death rate showed a statistically significant decrease between 199 and 1999 (Figure 39). Between 199 and 1999, 46 people died from drowning, at a
More information2019 Canada Winter Games Freestyle Ski Technical Package
2019 Canada Winter Games Freestyle Ski Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,
More informationHEALTH CARE SYSTEMS RESEARCH NETWORK
IRB APPROVAL OF HCSRN MULTI-SITE RESEARCH: FREQUENTLY ASKED QUESTIONS (AND ANSWERS) The goal of SOP HCSRN-001,, is to make human subjects review as efficient and timely as possible, while still recognizing
More informationUniversity of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)
University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP) I. OVERVIEW The purpose of this Standard Operating Procedure is to define a process for all University of Iowa
More informationARDS Network Investigators Response to the October 7, 2002 OHRP Letter
ARDS Network Investigators Response to the October 7, 2002 OHRP Letter March 12, 2003 A. Concerns, questions, and allegations regarding the ARMA trial (ARDSNet Study 01): (1) OHRP is concerned that the
More informationResearch Involving Human Subjects: AA 110.7
Research Involving Human Subjects: AA 110.7 Purpose To set forth certain human subjects rights and protections, and to establish a review process intended to ensure compliance with federal regulations
More informationLapse in IRB Approval
Office for the Protection of Research Subjects (OPRS) Institutional Review Board FWA# 00000083 Lapse in IRB Approval Version: 3.2; Date: 01/05/2016 Approved by: Human Protections Administrator, Director
More informationfor Walking with Pedometer Version 2/7/12 Step-by-Step Guide for Explaining Rx & Pedometer
Key idea Step-by-Step Guide for Explaining Rx & Pedometer Note: Can vary order of sections and expand different points to fit each patient's particular needs and circumstances. Script is illustrated using
More informationPaper prepared by the Secretariat
COMMISSION FOURTEENTH REGULAR SESSION Manila, Philippines 3 7 December 2017 REFERENCE DOCUMENT FOR REVIEW OF CMM 2005-03 AND FOR THE DEVELOPMENT OF HARVEST STRATEGIES UNDER CMM 2014-06 North Pacific Albacore
More informationSignature Date Date First Effective: Signature Date Revision Date:
Revision #10 TITLE: Continuation Review Page 1 of 10 Approved By: ORI Director Signature Date Date First Effective: 05-17-05 Approved By: Nonmedical IRB Chair Signature Date Approved By: Medical IRB Chair
More informationThe Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes. by Megan Brenner
The Effects of Chronic Creatine Supplementation on Performance and Body Composition of Female Athletes by Megan Brenner Thesis submitted to the Faculty of Virginia Polytechnic Institute and State University
More information2019 Canada Winter Games Archery Technical Package
2019 Canada Winter Games Archery Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements,
More informationSubmitting Continuing Reviews and/or Amendments to the IRB
Submitting Continuing Reviews and/or Amendments to the IRB Tufts-New England Medical Center Tufts University Health Sciences IRB Education Series 2006 Presentation may only be reused or reprinted with
More informationSIERRA-SACRAMENTO VALLEY EMS AGENCY PROGRAM POLICY REFERENCE NO. 474
SIERRA-SACRAMENTO VALLEY EMS AGENCY PROGRAM POLICY REFERENCE NO. 474 PURPOSE: To establish the requirements and responsibilities of an S-SV approved EMT / Public Safety Automatic External Defibrillation
More information2011 CANADA WINTER GAMES BOXING TECHNICAL PACKAGE
2011 CANADA WINTER GAMES BOXING TECHNICAL PACKAGE Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements, assist
More informationVersion 1. Submission Guide and Policies
Submission Guide and Policies Pearl IRB Investigator Manual Table of Contents 1.1 Pearl IRB overview... 3 1.2 What is the purpose of this manual?... 3 1.3 What is Human Research?... 3 1.4 What is the Human
More informationUNIVERSITY OF IDAHO 4-H MARKET ANIMAL PROJECT POLICY
UNIVERSITY OF IDAHO 4-H MARKET ANIMAL PROJECT POLICY 4-H Market Livestock Program Mission Statement. The mission of 4-H is to help youth acquire knowledge, develop life skills, and form attitudes that
More informationCitation for published version (APA): Canudas Romo, V. (2003). Decomposition Methods in Demography Groningen: s.n.
University of Groningen Decomposition Methods in Demography Canudas Romo, Vladimir IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More information